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cancer patients irrespective of drug is identiﬁed. The estimate combines the prediction 
of number of newly diagnosed and treated patients with the prediction of number of 
patients who were diagnosed previously and would probably be treated in a given 
year due to a relapse or progression of the primary malignant disease. In the second 
step patients are localised to individual drugs according to treatment scheme provided 
by the panel of experts, adjusted using information from clinical registries. RESULTS: 
The model currently provides predictions of potentially treated patients with quanti-
ﬁed uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) 
patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving 
bevacizumab for colorectal cancer, 300 (151; 449) patients receiving cetuximab for 
colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell 
lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number 
of patients requiring targeted anticancer therapy in the years to come. Final outcome 
is used by decision makers for planning of health care expenses in the Czech 
Republic.
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OBJECTIVES: The aim of this analysis is to compare the reimbursement rates for 
administration costs of triplet therapy bevacizumab-cisplatin-gemcitabine (BCG) 
versus doublet therapy cisplatin-pemetrexed (CP) for mNSCLC patients in France and 
German health care systems. METHODS: A systematic literature search performed 
in Medline, Embase, Cochrane, and Centre of Reviews and Dissemination databases 
identiﬁed 578 publications of anticancer agents. In addition, an evaluation of national 
reimbursement tariffs in both inpatient and outpatient settings was performed. 
Country-speciﬁc reimbursement structures were veriﬁed by two in-depth semi-struc-
tured expert oncologist interviews in each country. RESULTS: No publication includ-
ing reimbursement tariffs for the administration of anticancer agents was identiﬁed 
during the systematic literature review. The evaluation of the national reimbursement 
tariffs showed signiﬁcant costs for the administration service. The French GHS # 9606 
“Chimiothérapie pour tumeur, en séances” is the reimbursement tariff of one inpatient 
chemotherapy session valued at a385.77 (public sector). The chemotherapy home 
infusion tariff code “chemotherapy, intravenous treatment” is valued at a374.16 
irrespective of the number of injections administered. In Germany the inpatient 
 reimbursement tariff G-DRG # E71B “Neubildung der Atmungsorgane” refers to the 
indication “neoplasm” with a cost of a1.671 for an inpatient visit and a610.40 for 
an outpatient visit. In both reimbursement systems these are ﬂat rates irrespective of 
the number of chemotherapeutic drugs administered. CONCLUSIONS: When com-
paring the reimbursement for administrations of anticancer treatment combinations 
in France and Germany administration costs are unaffected by single, double or triple 
chemotherapy combinations. Therefore there is no difference in the cost of reimburse-
ment for administration for BCG versus CP.
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OBJECTIVES: Despite implementation of radical cost control measures, pharmaceuti-
cal expenditure is expected to keep increasing due to highly innovative, expensive 
drugs, including immunotherapeutics. The objective of this study was to understand 
how different markets are responding to cost containment pressures, using a compare-
and-contrast approach of reimbursement decisions for three recently approved treat-
ments for metastatic renal cell carcinoma (mRCC). Based on the ﬁndings we propose 
fundamentals to build acceptable reimbursement strategies for AI, including cancer 
vaccines. METHODS: We examined commonalities and differences of three drugs 
for mRCC, assessing drug costs, health technology assessments (HTA), and reimburse-
ment decisions across 7 countries with similar pharmaceutical funding schemes 
(Canada, France, Germany, Italy, Spain, Sweden, and the UK). In each of the 7 coun-
tries primary reimbursement criteria for these drugs were identiﬁed, local HTAs were 
reviewed, and speciﬁc qualitative research with local payers and experts was con-
ducted. For country comparisons, drug treatment costs were calculated from a payer 
perspective (6 weeks therapy). RESULTS: Treatment cost differences in the seven 
countries were minimal and mostly related to exchange rates indicating that, for 
innovative drugs, price convergence has been achieved in these countries. More than 
70% of the total HTA evaluations conducted involved immunotherapeutics. Only the 
SMC assessment recommended against the use of the 3 studied drugs. Most countries 
apply or are studying some type of risk sharing scheme or access/restriction program 
for forthcoming drugs. CONCLUSIONS: Most payers accept high priced drugs; 
however, they certainly restrict patient access or set up different types of agreements 
with suppliers to be able to maintain budget control. Current reimbursement schemes 
in the countries studied will need to evolve according to similar parameters in order 
to give access to highly complex therapies as AI. In each country, the feasibility of 
implementing processes to track drug use, cost and outcomes will determine how these 
reimbursement schemes develop.
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OBJECTIVES: Colorectal cancer (CRC) is the third leading cause of cancer mortality 
in the US with disparities in risk between rural and urban patients. The aim of the 
study was to: 1) describe the characteristics of hospital admissions, 2) compare the 
length of stay and in-hospital deaths in rural and urban West Virginia residents with 
a primary diagnosis of CRC. METHODS: Data from the Health Care Cost and 
 Utilization Project, State Inpatient Database for the years 2003, 2005, 2006 and 
2007 were used to perform analyses of all discharges with a primary diagnosis of 
CRC. Chi square tests compared categorical descriptive statistics between rural and 
urban cases. One-way ANOVA compared mean length of stay based on rural-urban 
category. RESULTS: Admissions for CRC as a primary diagnosis decreased constantly 
from 882 in 2003 to 787 in 2007. In-hospital deaths rose steadily from 5.1% in 2003 
to 7% in 2006, but fell to 5.7% in 2007. Mean ages ranged between 69.6 years and 
70.3 years and percentage of female admissions ranged between 53.1% and 55.2% 
over the four years. A greater proportion of patients from large metros (17.4%) died 
in-hospital compared to small metros (7.0%), micropolitan (4.4%) and rural (5.2%) 
areas (p  0.001). Leading primary payer was Medicare for all four locations. Rural 
patients had the shortest mean length of stay (9.0 days). The mean length of stay dif-
fered signiﬁcantly between rural (9.0 days) and micropolitan (10.0 days) patients. 
CONCLUSIONS: Colorectal cancer provides a signiﬁcant burden to the health care 
system in West Virginia. Unlike previously reported in certain other states and coun-
tries, a greater proportion of urban residents in West Virginia are dying in-hospital 
due to CRC. The reasons for these disparities go beyond demographic differences 
between rural-urban residents and need to be explored.
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OBJECTIVES: Chemotherapy-induced vomiting (CIV) is a frequent side effect of 
cancer treatment, with debilitating symptoms and negative effects on quality of life. 
CIV may be acute (within 24 hours of chemotherapy) or delayed (up to 7 days later). 
Different doses of PAL are available but the ideal one is still unknown. A recent meta-
analysis demonstrated that PAL is more effective than other serotonin inhibitors in 
preventing nausea and CIV in patients receiving MoHE chemotherapy. We aimed to 
perform a SR and MA of all randomized controlled trials (RCT) comparing PAL 
0.25 mg (or 0.3–1 mcg/kg) to PAL 0.75 mg (or 10 mcg/kg) as single intravenous doses 
in this setting of patients. METHODS: We searched several databases: MEDLINE, 
EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of 
acute and delayed vomiting. The side effects of each treatment were analyzed. A sub-
group analysis was planned and performed to evaluate the inﬂuence of the use of 
corticosteroids. The results of individual studies were pooled in MA, using the 
RevMan 5.1 software. The results are expressed as Risk Ratio (RR) and the corre-
spondent 95% Conﬁdence Interval (CI). RESULTS: Eight studies with 1674 patients 
were included. There was no difference between the efﬁcacy of the evaluated doses in 
preventing either acute (RR  1.04; CI  95%  0.91 to 1.18; p  0.60) or delayed 
vomiting (RR  1.01; CI95%  0.90 to 1.13; p  0.89). There were no differences in 
side effects either: headache (RR  0.88; CI95%  0.64 to 1.20; p  0.41), dizziness 
(RR  1.20; CI95%  0.33 to 4.35; p  0.78), constipation (RR  0.67; CI95%  
0.42 to 1.06; p  0.09) or diarrhea (RR  1.51; CI95%  0.43 to 5.31; p  0.52). The 
subgroup analysis found that the addition of corticosteroids had no impact on the 
efﬁcacy of PAL. CONCLUSIONS: Both doses of PAL have equal efﬁcacy and safety 
proﬁle in preventing CIV in patients receiving MoHE chemotherapy. The choice of 
scheme, in this situation, must be the least costly one.
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OBJECTIVES: To perform a review of the published meta-analyses, systematic reviews 
and health technology assessments reports (HTAR) which evaluated the use of ritux-
imab for the treatment of non-Hodgkin lymphoma (NHL) regarding its beneﬁts, safety 
proﬁle and cost-effectiveness. METHODS: A search of MEDLINE, Lilacs, Cochrane 
library, Web of science and INAHTA websites from 1990 to 2009 was conducted. 
The following MESH terms were used: “Meta-Analysis”, “Systematic Reviews”, 
“Lymphoma, Non-Hodgkin”, “Lymphoma, Large B-Cell, Diffuse” and “rituximab”. 
Included studies were those which evaluated the use of rituximab alone and/or in 
combination with other therapies in ﬁrst line, second line and maintenance therapy 
for naive, refractory patients or relapsed disease in different patient characteristics. 
